212 related articles for article (PubMed ID: 18041880)
21. The appearance of pustular psoriasis during antitumor necrosis factor therapy.
Goncalves DP; Laurindo I; Scheinberg MA
J Clin Rheumatol; 2006 Oct; 12(5):262. PubMed ID: 17023816
[No Abstract] [Full Text] [Related]
22. Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis.
Chan CY; Browning JC; Larsen F; Hsu S
Dermatol Online J; 2008 Sep; 14(9):12. PubMed ID: 19061594
[TBL] [Abstract][Full Text] [Related]
23. Sequential use of biologic therapy in rheumatoid arthritis.
Buch MH
Curr Opin Rheumatol; 2010 May; 22(3):321-9. PubMed ID: 20190641
[TBL] [Abstract][Full Text] [Related]
24. Use of infliximab in a patient with rheumatoid arthritis and chronic hepatitis B.
Doubrawa E; Ricca RA; Malucelli TO; Pizzol VI; Barros DH; Paiva ES
Rev Bras Reumatol; 2012 Aug; 52(4):653-5. PubMed ID: 22885430
[TBL] [Abstract][Full Text] [Related]
25. [TNF antagonists in therapy of rheumatoid arthritis].
Oberpichler-Schwenk H
Med Monatsschr Pharm; 1999 Nov; 22(11):334-9. PubMed ID: 10596266
[No Abstract] [Full Text] [Related]
26. Biologic therapy for rheumatoid arthritis.
Klippel JH
N Engl J Med; 2000 Nov; 343(22):1640-1. PubMed ID: 11096174
[No Abstract] [Full Text] [Related]
27. Drug Insight: abatacept for the treatment of rheumatoid arthritis.
Ruderman EM; Pope RM
Nat Clin Pract Rheumatol; 2006 Dec; 2(12):654-60. PubMed ID: 17133250
[TBL] [Abstract][Full Text] [Related]
28. Interstitial pneumonitis and anti-tumor necrosis factor-alpha therapy.
Roos JC; Chilvers ER; Ostor AJ
J Rheumatol; 2007 Jan; 34(1):238-9; author reply 239. PubMed ID: 17216703
[No Abstract] [Full Text] [Related]
29. Letter: A case of generalized guttate psoriasis induced by etanercept with relapse after abatacept.
Brigant F; Clavel G; Chatelain D; Lok C; Chaby G
Dermatol Online J; 2011 Jun; 17(6):11. PubMed ID: 21696691
[TBL] [Abstract][Full Text] [Related]
30. Psoriasiform lesions appearing in three patients with rheumatoid arthritis during therapeutic administration of abatacept, a selective inhibitor of T-cell costimulation.
Konsta M; Rallis E; Karameris A; Stratigos A; Sfikakis PP; Iliopoulos A
J Eur Acad Dermatol Venereol; 2012 Feb; 26(2):257-8. PubMed ID: 22280512
[No Abstract] [Full Text] [Related]
31. Bone mineral density in patients with rheumatoid arthritis treated with infliximab.
Vis M; Voskuyl AE; Wolbink GJ; Dijkmans BA; Lems WF;
Ann Rheum Dis; 2005 Feb; 64(2):336-7. PubMed ID: 15647447
[No Abstract] [Full Text] [Related]
32. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis.
Salliot C; Finckh A; Katchamart W; Lu Y; Sun Y; Bombardier C; Keystone E
Ann Rheum Dis; 2011 Feb; 70(2):266-71. PubMed ID: 21097801
[TBL] [Abstract][Full Text] [Related]
33. [Targeting CD20 in rheumatoid arthritis].
Saito K; Tanaka Y
Nihon Rinsho; 2007 Jul; 65(7):1243-9. PubMed ID: 17642239
[TBL] [Abstract][Full Text] [Related]
34. Abatacept: new drug. Rheumatoid arthritis: after failure of TNF alpha antagonists and rituximab.
Prescrire Int; 2008 Dec; 17(98):232. PubMed ID: 19422143
[No Abstract] [Full Text] [Related]
35. Clinical trial outcome of anti-tumour necrosis factor alpha therapy in rheumatic arthritis.
Choy E
Cytokine; 2004 Nov 21-Dec 7; 28(4-5):158-61. PubMed ID: 15588689
[TBL] [Abstract][Full Text] [Related]
36. Drug-induced lupus erythematosus in a patient treated with adalumimab.
Spillane AP; Xia Y; Sniezek PJ
J Am Acad Dermatol; 2007 May; 56(5 Suppl):S114-6. PubMed ID: 17434034
[No Abstract] [Full Text] [Related]
37. Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor alpha antagonists and disease-modifying antirheumatic drugs.
Curtis JR; Martin C; Saag KG; Patkar NM; Kramer J; Shatin D; Allison J; Braun MM
Arthritis Rheum; 2007 Mar; 57(2):343-6. PubMed ID: 17330283
[No Abstract] [Full Text] [Related]
38. [Mechanism of action of biological disease--modifying antirheumatic drugs].
Takahashi N; Ishiguro N
Nihon Rinsho; 2016 Jun; 74(6):882-6. PubMed ID: 27311173
[No Abstract] [Full Text] [Related]
39. COBRA combination therapy in daily practice--getting back to the future.
Boers M
Rheumatology (Oxford); 2008 Jan; 47(1):1-2. PubMed ID: 18077485
[No Abstract] [Full Text] [Related]
40. The efficacy and tolerability of newer biologics in rheumatoid arthritis: best current evidence.
Siddiqui MA
Curr Opin Rheumatol; 2007 May; 19(3):308-13. PubMed ID: 17414961
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
